Madrigal Pharmaceuticals MDGL reported a fourth-quarter 2025 loss of $2.57 per share, in contrast to the Zacks Consensus ...
Fourth-quarter and full-year 2025 Rezdiffra® (resmetirom) net sales of $321.1 million and $958.4 million, respectively As of year-end 2025, more ...
Reported steady patient growth, ending Q4 2025 with over 36,250 patients, driven by high prescriber confidence and real-world ...
POWHATAN, Va. ( WWBT /Gray News) - A Virginia grandfather received a life-saving donation from a family member: his ...
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 30% of adults, with about 30% of cases progressing to metabolic dysfunction-associated steatohepatitis (MASH), ...
Madrigal Pharmaceuticals is reiterated as a Strong Buy ahead of Q4 earnings, with a 12-month price target of $665, implying ...
Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human ...
Amid rising cases of lifestyle diseases, doctors have raised concerns over the growing incidence of fatty liver disease, warning that excessive alcohol consumption, unhealthy eating habits, obesity ...
Q4 2025 earnings call recap: revenue/EBITDA growth, 2026 guidance, Shibo China deal, and Xifaxan risks—read the key takeaways.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results